Degron Therapeutics Inc. closed a $40 million series A extension round that will see the company advance its molecular glue degraders targeting previously undruggable or insufficiently drugged proteins.
There are real world demonstrations of how autonomous artificial intelligence agents are poised to disrupt biomedical research, according to two papers published May 19 in Nature. Each describes an AI system that assists across the piece, from generating hypotheses to designing experiments, analyzing the data and refining hypotheses in the light of new data.
Create Medicines Inc. closed a $122 million series B financing round to support its pipeline of therapies that use mRNAs delivered via liquid nanoparticles to express chimeric antigen receptors (CARs) in T cells, NK cells and myeloid cells inside the body of patients. The Cambridge, Mass.-based company estimates the capital will last through 2028, providing the opportunity for multiple clinical readouts of its various products.
Showing a significant efficacy signal in a phase II trial, Relay Therapeutics Inc.’s zovegalisib (RLY-2608) achieved a 60% volumetric response in patients with PIK3CA-driven vascular anomalies (VAs). The isoform-selective PI3Ka inhibitor is in late-stage clinical trials with various combinations for P13Ka-mutated, HR+/HER2- advanced breast cancer, with VAs representing a second indication for which Leerink Partners analyst Andrew Berens forecasts $2.8 billion in peak revenues.
Prelude Therapeutics Inc. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)- and SMARCA4-targeting moiety.
Kimia Therapeutics Inc. has disclosed new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, autoimmune and viral infections.
Shanghai Meiyue Biotech Development Co. Ltd. has synthesized new benzopyrimidine compounds acting as histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors potentially useful for the treatment of cancer, autoimmune disease, metabolic diseases, gastrointestinal and inflammatory disorders.
Iksuda Therapeutics Ltd. and UCL Business Ltd. have prepared new antibody-drug conjugates comprising antibodies targeting B7 homolog 3 (B7-H3, CD276) covalently linked to cytotoxic drug, designed for potential use in the treatment of cancer.
Antibody-drug conjugates (ADCs) with a dual payload, which deliver two distinct cytotoxic agents via a single antibody, are emerging therapeutics developed to address the limitations of classic ADCs. Primelink Biotherapeutics (Shenzhen) Co. Ltd. recently presented data for their dual-payload ADCs, highlighting PLB-015, which carries a TOP1 inhibitor and an ATR inhibitor with an anti-HER2 antibody and is designed to inhibit the DNA damage response activated by cancer cells when harmed.
Researchers at the School of Pharmacy and Biomolecular Sciences from the Royal College of Surgeons in Ireland and collaborating institutions have detailed the design, synthesis and biological evaluation of a new series of triazine-based multitarget inhibitors aimed at dual inhibition of PI3K and HDAC for breast cancer therapy.
RSS
